JP2016525522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525522A5 JP2016525522A5 JP2016527107A JP2016527107A JP2016525522A5 JP 2016525522 A5 JP2016525522 A5 JP 2016525522A5 JP 2016527107 A JP2016527107 A JP 2016527107A JP 2016527107 A JP2016527107 A JP 2016527107A JP 2016525522 A5 JP2016525522 A5 JP 2016525522A5
- Authority
- JP
- Japan
- Prior art keywords
- expression construct
- bacterial
- viral
- therapeutic anti
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003814 Interleukin-10 Human genes 0.000 claims 31
- 108090000174 Interleukin-10 Proteins 0.000 claims 31
- 238000000034 method Methods 0.000 claims 24
- 230000001580 bacterial effect Effects 0.000 claims 13
- 230000003612 virological effect Effects 0.000 claims 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 229940076144 interleukin-10 Drugs 0.000 claims 8
- 208000012659 Joint disease Diseases 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 4
- 210000001503 joint Anatomy 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 235000004400 serine Nutrition 0.000 claims 2
- 235000008521 threonine Nutrition 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000001513 elbow Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 210000001624 hip Anatomy 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000002832 shoulder Anatomy 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
Claims (24)
- 非ヒト対象における炎症性関節疾患を治療する方法であって、
炎症を起こした前記関節に、治療に有効な量の細菌又はウイルスIL−10発現構築物を含む治療用抗炎症組成物を注射するステップを含み、
前記IL−10発現構築物が、細菌骨格又はウイルス骨格と、インターロイキン−10をコード化する核酸配列とを含む方法。 - 前記IL−10発現構築物が、アジュバントと一緒に投与される、請求項1に記載の方法。
- 前記アジュバントが、D−マンノース、スクロース、グルコース、リン酸カルシウム、デンドリマー、オリゴヌクレオチド、高分子量ヒアルロン酸、又はリポソームから選択される、請求項2に記載の方法。
- 非ヒト対象における炎症性関節疾患を治療する方法であって、
炎症を起こした前記関節に、治療に有効な量の細菌又はウイルスIL−10発現構築物を含む治療用抗炎症組成物を注射するステップを含み、
前記IL−10発現構築物が、細菌骨格又はウイルス骨格と、インターロイキン−10をコード化する核酸配列と;前記発現構築物をカプセル化する微小粒子とを含む方法。 - 前記微小粒子がポリマーであり、該ポリマーが、乳酸−グリコール酸共重合体を含む、請求項4に記載の方法。
- ポリマーが、50:50乳酸−グリコール酸共重合体を含む、請求項5に記載の方法。
- 非ヒト対象における炎症性関節疾患を治療する方法であって、
炎症を起こした前記関節に、1〜500μgの細菌又はウイルスIL−10発現構築物を含む治療用抗炎症組成物を注射するステップを含み、
前記IL−10発現構築物が、細菌骨格又はウイルス骨格と、インターロイキン−10をコード化する核酸配列と;5〜1000μgのD−マンノースとを含む方法。 - D−マンノースが、前記IL−10発現構築物と一緒に投与される、請求項7に記載の方法。
- D−マンノースが、前記IL−10発現構築物の投与の最大10日前に投与される、請求項7に記載の方法。
- インターロイキン−10をコード化する前記核酸配列が、アミノ酸129位の野生型フェニルアラニンのアミノ酸置換を有する、請求項1〜9のいずれか一項に記載の方法。
- 前記アミノ酸置換が、セリン、アラニン、トレオニン又はシステインの群から選択される、請求項10に記載の方法。
- インターロイキン−10をコード化する前記核酸配列が、IL−10F129Sをコード化する、請求項11に記載の方法。
- 前記細菌又はウイルスIL−10発現構築物がプラスミドDNAであり、該プラスミドDNAが、IL−10コード配列の5’側に少なくとも1つの核ターゲティング配列を含む、請求項1〜12のいずれか一項に記載の方法。
- 前記細菌又はウイルスIL−10発現構築物がプラスミドDNAであり、該プラスミドDNAが、IL−10コード配列の3’側に少なくとも1つの核ターゲティング配列を含む、請求項1〜12のいずれか一項に記載の方法。
- 前記細菌又はウイルスIL−10発現構築物がプラスミドDNAであり、該プラスミドDNAが、IL−10コード配列の5’及び3’側の両方に少なくとも1つの核ターゲティング配列を含む、請求項1〜12のいずれか一項に記載の方法。
- 治療用抗炎症組成物が希釈剤をさらに含む、請求項1〜15のいずれか一項に記載の方法。
- 前記関節が、膝、肘、手首、足首、腰、肩、又は脊椎である、請求項1〜16のいずれか一項に記載の方法。
- 前記炎症性関節疾患が、関節炎、腱炎、滑液包炎、靭帯の炎症、滑膜炎、痛風、及び全身性エリテマトーデスである、請求項1〜17のいずれか一項に記載の方法。
- 前記炎症性関節疾患が、骨関節炎である、請求項18に記載の方法。
- 非ヒト対象における炎症性関節疾患を治療する方法であって、
炎症を起こした前記関節に、1〜500μgの細菌又はウイルスIL−10発現構築物を含む治療用抗炎症組成物を注射するステップを含み、
前記IL−10発現構築物が、細菌骨格又はウイルス骨格と、IL−10F129Sをコード化する核酸配列と、IL−10コード配列の5’又は3’側のいずれか又は両方に少なくとも1つの核ターゲティング配列と;5〜1000μgのD−マンノースとを含む方法。 - 非ヒト対象における炎症性関節疾患の治療するための治療用抗炎症組成物であって、
治療に有効な量の細菌又はウイルスIL−10発現構築物を含み、
前記IL−10発現構築物が、細菌骨格又はウイルス骨格と、インターロイキン−10をコード化する核酸配列とを含む治療用抗炎症組成物。 - インターロイキン−10をコード化する前記核酸配列が、アミノ酸129位の野生型フェニルアラニンのアミノ酸置換を有する、請求項21に記載の治療用抗炎症組成物。
- 前記アミノ酸置換が、セリン、アラニン、トレオニン又はシステインの群から選択される、請求項22に記載の治療用抗炎症組成物。
- インターロイキン−10をコード化する前記核酸配列が、IL−10 F129S をコード化する、請求項23に記載の治療用抗炎症組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361847851P | 2013-07-18 | 2013-07-18 | |
US61/847,851 | 2013-07-18 | ||
PCT/US2014/047071 WO2015009955A1 (en) | 2013-07-18 | 2014-07-17 | Methods for the treatment of inflammatory joint disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019199475A Division JP7066669B2 (ja) | 2013-07-18 | 2019-11-01 | 炎症性関節疾患の治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016525522A JP2016525522A (ja) | 2016-08-25 |
JP2016525522A5 true JP2016525522A5 (ja) | 2017-06-29 |
Family
ID=52346725
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016527107A Withdrawn JP2016525522A (ja) | 2013-07-18 | 2014-07-17 | 炎症性関節疾患の治療方法 |
JP2019199475A Active JP7066669B2 (ja) | 2013-07-18 | 2019-11-01 | 炎症性関節疾患の治療方法 |
JP2021180762A Pending JP2022031682A (ja) | 2013-07-18 | 2021-11-05 | 炎症性関節疾患の治療方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019199475A Active JP7066669B2 (ja) | 2013-07-18 | 2019-11-01 | 炎症性関節疾患の治療方法 |
JP2021180762A Pending JP2022031682A (ja) | 2013-07-18 | 2021-11-05 | 炎症性関節疾患の治療方法 |
Country Status (14)
Country | Link |
---|---|
US (4) | US10512672B2 (ja) |
EP (2) | EP3021873B8 (ja) |
JP (3) | JP2016525522A (ja) |
CY (2) | CY1120946T1 (ja) |
DK (2) | DK3021873T3 (ja) |
ES (2) | ES2700826T3 (ja) |
HR (2) | HRP20181913T1 (ja) |
HU (2) | HUE042463T2 (ja) |
LT (2) | LT3021873T (ja) |
PL (2) | PL3369435T3 (ja) |
PT (2) | PT3369435T (ja) |
RS (2) | RS57974B1 (ja) |
SI (2) | SI3369435T1 (ja) |
WO (1) | WO2015009955A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57974B1 (sr) | 2013-07-18 | 2019-01-31 | Xalud Therapeutics Inc | Sastavi za lečenje inflamatornog oboljenja zglobova |
CN109477085B (zh) * | 2016-04-22 | 2023-08-01 | 萨鲁德医疗公司 | 增强白细胞介素10的抗炎作用的方法和组合物 |
CN116209459A (zh) * | 2020-06-26 | 2023-06-02 | 美国安进公司 | Il-10突变蛋白及其融合蛋白 |
WO2023114958A1 (en) * | 2021-12-16 | 2023-06-22 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
US6312680B1 (en) | 1990-06-29 | 2001-11-06 | Timothy R. Mosmann | Methods of treatment using cytokine synthesis inhibitory factor |
HU220103B (hu) | 1992-08-20 | 2001-10-28 | Schering-Plough Corp. | IL-10 új alkalmazása |
US5922018A (en) | 1992-12-21 | 1999-07-13 | Artann Corporation | Method for using a transrectal probe to mechanically image the prostate gland |
US5373317B1 (en) | 1993-05-28 | 2000-11-21 | Welch Allyn Inc | Control and display section for borescope or endoscope |
EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
SK283096B6 (sk) | 1994-07-05 | 2003-02-04 | Steeno Research Group A/S | Imunomodulátory |
CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
US5716804A (en) | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
WO1998024469A1 (en) | 1996-12-05 | 1998-06-11 | University Of Florida | Il-10 and tgf-beta for treating autoimmune disease |
US6201880B1 (en) | 1996-12-31 | 2001-03-13 | Electro-Optical Sciences | Method and apparatus for electronically imaging a tooth through transillumination by light |
US5783567A (en) | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
AU3063899A (en) | 1998-03-17 | 1999-10-11 | Schering Corporation | Use of il-10 to treat major depressive disorder |
WO1999056784A2 (en) | 1998-05-06 | 1999-11-11 | Transgene S.A. | Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10 |
US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US6165754A (en) | 1999-06-08 | 2000-12-26 | Cornell Research Foundation, Inc. | Method of expressing an exogenous nucleic acid |
US20050129669A1 (en) | 1999-06-21 | 2005-06-16 | Transkaryotic Therapies, Inc., A Massachusetts Corporation | DNA construct for effecting homologous recombination and uses thereof |
US6875748B2 (en) | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
AU2002217929A1 (en) | 2000-11-28 | 2002-06-11 | Sangamo Biosciences, Inc. | Modulation of gene expression using insulator binding proteins |
JP2004515527A (ja) | 2000-12-13 | 2004-05-27 | メルクル・ゲーエムベーハー | 放出特性改良微粒子およびその製造方法 |
WO2002083080A2 (en) * | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
WO2002087594A1 (en) | 2001-04-30 | 2002-11-07 | The Regents Of The University Of California | Non-viral vesicle vector for cardiac specific gene delivery |
JP4578735B2 (ja) | 2001-08-28 | 2010-11-10 | オリンパス株式会社 | 内視鏡画像ファイリングシステム |
CA2361462A1 (en) | 2001-11-07 | 2003-05-08 | Katherine A. High | Induction of tolerance to a therapeutic polypeptide |
JP2003146909A (ja) | 2001-11-07 | 2003-05-21 | Children's Hospital Of Philadelphia | 治療用ポリペプチドに対する免疫寛容の誘導 |
US6967018B2 (en) | 2002-01-11 | 2005-11-22 | Applied Genetic Technologies Corporation | Adiponectin gene therapy |
US20070003518A1 (en) | 2002-04-19 | 2007-01-04 | Atkinson Mark A | Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases |
WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
US20040186357A1 (en) | 2002-08-20 | 2004-09-23 | Welch Allyn, Inc. | Diagnostic instrument workstation |
US7897380B2 (en) | 2002-08-29 | 2011-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
US20040142893A1 (en) | 2002-10-21 | 2004-07-22 | Uichi Ikeda | Methods for treating and preventing vascular disease |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
US7530946B2 (en) | 2003-08-15 | 2009-05-12 | Scimed Life Systems, Inc. | Compact endoscope |
US7276486B2 (en) | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
EP1773381A4 (en) * | 2004-07-01 | 2008-07-02 | Univ Pittburgh Of The Commonwe | EXOSOMES IMMUNOSUPPRESSANTS |
US20060073119A1 (en) | 2004-09-01 | 2006-04-06 | Avigen, Inc. | Methods for treating neurodegenerative disorders |
US20100028296A1 (en) | 2005-05-02 | 2010-02-04 | Chavez Raymond A | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
ES2696824T3 (es) | 2005-05-31 | 2019-01-18 | Univ Colorado Regents | Métodos para suministrar genes |
DE602006011311D1 (de) * | 2005-05-31 | 2010-02-04 | Univ Colorado | Il-10 mutante |
WO2007016501A2 (en) | 2005-08-01 | 2007-02-08 | The University Of Chicago | Compositions and method for brain specific targeted delivery of therapeutic agents |
US20100196492A1 (en) | 2007-03-08 | 2010-08-05 | Green Jordan J | Electrostatic coating of particles for drug delivery |
US7846428B2 (en) | 2007-10-05 | 2010-12-07 | Merial Limited | Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
EP2651407B1 (en) * | 2010-12-15 | 2016-12-21 | Olatec Industries LLC | 3-methanesulfonylpropionitrile for treating inflammation and pain |
US20150044281A1 (en) | 2012-01-06 | 2015-02-12 | The Regents Of The University Of Colorado, A Body Corporate | Methods for the treatment of multiple sclerosis and other demyelinating disorders |
RS57974B1 (sr) | 2013-07-18 | 2019-01-31 | Xalud Therapeutics Inc | Sastavi za lečenje inflamatornog oboljenja zglobova |
CN109477085B (zh) | 2016-04-22 | 2023-08-01 | 萨鲁德医疗公司 | 增强白细胞介素10的抗炎作用的方法和组合物 |
-
2014
- 2014-07-17 RS RS20181419A patent/RS57974B1/sr unknown
- 2014-07-17 SI SI201431402T patent/SI3369435T1/sl unknown
- 2014-07-17 WO PCT/US2014/047071 patent/WO2015009955A1/en active Application Filing
- 2014-07-17 PL PL18167083T patent/PL3369435T3/pl unknown
- 2014-07-17 EP EP14826787.5A patent/EP3021873B8/en active Active
- 2014-07-17 ES ES14826787T patent/ES2700826T3/es active Active
- 2014-07-17 JP JP2016527107A patent/JP2016525522A/ja not_active Withdrawn
- 2014-07-17 HU HUE14826787A patent/HUE042463T2/hu unknown
- 2014-07-17 DK DK14826787.5T patent/DK3021873T3/en active
- 2014-07-17 LT LTEP14826787.5T patent/LT3021873T/lt unknown
- 2014-07-17 US US14/905,915 patent/US10512672B2/en active Active
- 2014-07-17 PT PT181670837T patent/PT3369435T/pt unknown
- 2014-07-17 EP EP18167083.7A patent/EP3369435B1/en active Active
- 2014-07-17 RS RS20191473A patent/RS59735B1/sr unknown
- 2014-07-17 ES ES18167083T patent/ES2760902T3/es active Active
- 2014-07-17 PL PL14826787T patent/PL3021873T3/pl unknown
- 2014-07-17 PT PT14826787T patent/PT3021873T/pt unknown
- 2014-07-17 DK DK18167083T patent/DK3369435T3/da active
- 2014-07-17 HU HUE18167083A patent/HUE046944T2/hu unknown
- 2014-07-17 SI SI201430972T patent/SI3021873T1/sl unknown
- 2014-07-17 LT LTEP18167083.7T patent/LT3369435T/lt unknown
-
2018
- 2018-11-16 HR HRP20181913TT patent/HRP20181913T1/hr unknown
- 2018-11-28 CY CY181101297T patent/CY1120946T1/el unknown
-
2019
- 2019-10-31 US US16/670,987 patent/US20200093892A1/en not_active Abandoned
- 2019-11-01 JP JP2019199475A patent/JP7066669B2/ja active Active
- 2019-11-12 HR HRP20192043TT patent/HRP20192043T1/hr unknown
- 2019-12-03 CY CY20191101267T patent/CY1122673T1/el unknown
-
2021
- 2021-11-05 JP JP2021180762A patent/JP2022031682A/ja active Pending
-
2022
- 2022-06-21 US US17/845,101 patent/US20220313785A1/en not_active Abandoned
-
2023
- 2023-01-25 US US18/159,161 patent/US20230158114A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016525522A5 (ja) | ||
Holleran et al. | The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease | |
Melzer et al. | Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil” | |
JP2017515470A5 (ja) | ||
HRP20192057T1 (hr) | Sastavi koji sadrže bakterijske sojeve | |
HRP20192043T1 (hr) | Pripravak za liječenje upalne bolesti zgloba | |
JP2016539946A5 (ja) | ||
JP2015007098A5 (ja) | ||
JP2016505635A5 (ja) | ||
MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
CY1123760T1 (el) | Ανασυνδυασμενοι φορεις aav που εκφραζουν οστεοπροστατευτικα γονιδια, που περιλαμβανουν has2 και λουμπρικινη, χρησιμοι στην θεραπευτικη αγωγη οστεοαρθριτιδας και συναφων παθησεων των αρθρωσεων στα θηλαστικα | |
HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
JP2015517803A5 (ja) | ||
NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
JP2014509852A5 (ja) | ||
JP2015514132A5 (ja) | ||
JP2015532097A5 (ja) | ||
Gibson | Engineered microRNA therapeutics | |
JP2020037562A5 (ja) | ||
Toyoda et al. | Candidates for intra-articular administration therapeutics and therapies of osteoarthritis | |
JP2013518599A5 (ja) | ||
WO2019197563A3 (en) | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation | |
JP2017523783A5 (ja) | ||
Kormschikov et al. | PECULIARITIES OF CHRONIC INFLAMMATORY PROCESS IN GASTRIC MUCOSA DEPENDING ON MOLECULAR-GENETIC CHARACTERISTIC OF HELICOBACTER PYLORI IN ADOLESCENTS | |
Koonin | The double-edged sword of Lamarck Comment on “Diversity, evolution, and therapeutic applications of small RNAs in prokaryotic and eukaryotic immune systems” by Edwin L. Cooper and Nicola Overstreet |